Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Lesson from Clinical Practice

Low flow nasal oxygen supplementation in addition to non-rebreathing mask: An alternative to high flow nasal cannula oxygenation for acute hypoxemic COVID-19 patients in resource limited settings

Amarjeet Kumar a,∗, Chandni Sinha b, Abhyuday Kumar b, Poonam Kumari b, Neeraj Kumar b, Ajeet Kumar b, Prabhat Kumar Singh c

a Department of Trauma and Emergency, AIIMS, Patna, India
b Department of Anaesthesiology, AIIMS, Patna, India
c AIIMS, Patna, India

Keywords:
Acute hypoxic respiratory failure COVID-19 High flow nasal cannula (HFNC) Non-rebreathing mask

Article history:
Received 5 December 2020
Received in revised form 13 February 2021
Accepted 14 February 2021

Abstract
Approximately 14% COVID-19 patients, develop acute hypoxic respiratory failure. A high flow nasal cannula device might be preferred to obtain an oxygen saturation above 90% in these cases. In resource limited settings, where high flow nasal cannula is not an option, additional low flow oxygen therapy through nasal prongs could be added to non-rebreathing mask with a reservoir bag. The possible mechanisms of the improved oxygenation could be: 1. improved oxygen-air mixing in large airways, 2. increased oxygen concentration inside the non-rebreathing mask, 3. decrease in rebreathing of carbon-dioxide from the non-rebreathing mask. This method of oxygen supplementation is easy to assemble, cost-effective and helpful in management of acute hypoxemic COVID-19 patients, whenever there is crisis of high flow nasal cannula machine. Its effectiveness needs to be assessed by a randomized controlled trial.

© 2021 Elsevier Ltd. All rights reserved.

1. Introduction

Approximately 14% patients diagnosed to have COVID-19 infection develop acute hypoxic respiratory failure. Literature reveal 5% of these patients require admission in intensive care unit [1]. Severe hypoxemia in such patients can be attributed to high physiological dead space, as compared to previously published series of non-COVID-19 acute respiratory distress syndrome patients [2]. For acute hypoxemic failure in these cases, a high flow nasal cannula (HFNC) device is preferred to obtain an oxygen saturation (SaO2) above 90% [3]. The HFNC oxygenation is a well-known technique allowing heated and humidified gas with a maximum flow rate of 70 L/min and an adjustable oxygen fraction. Non-rebreathing masks have an additional one-way valve that prevents room air entrainment and rebreathing of exhaled gases.

Non-rebreathing mask with a reservoir bag can deliver an FiO2 above 0.8, provided there is a good mask fit, and airflow is more than three times of minute ventilation. However, there is always some rebreathing due to accumulation of exhaled gas in mask, which is not vented out.

We propose the use of additional low flow oxygen therapy through nasal prongs (6 L/min) along with a non-rebreathing mask in patients whose oxygen requirement is not met by non-rebreathing mask alone. This technique combines the principle of HFNC (by low flow oxygen through nasal cannula) and oxygen through reservoir bag of the non-rebreathing mask.

Case 1: A 62-year-old female COVID-19 patient without any comorbidities presented with respiratory distress to our intensive care unit. The patient was started on remdesivir, dexamethasone, low molecular weight heparin, and put on supplemental oxygenation with non-rebreathing mask at 15 L/min. Chest X-ray revealed severe involvement of both the lungs. The arterial blood gas analysis after 1 h of non-rebreathing mask trial showed (PaO2/Fio2<100) with a pH of 7.50, a PaCO2 of 29.8 mmHg, a PaO2 of 61.5 mmHg, and Na 133, K 4.25, bicarbonate of 20.4. She became

https://doi.org/10.1016/j.tacc.2021.02.004
2210-8440/© 2021 Elsevier Ltd. All rights reserved.
tachypnoeic with a respiratory rate of >35 and peripheral oxygen saturation less than 90%. Extra-oxygen through nasal prongs at 6 L/min [Fig. 1] was added. After implementation of supplementary oxygen for 30 min, we found improvement in oxygen saturation (SaO2 >95%) with arterial blood gases, showing PaO2 88 mmHg and PaCO2 38 mmHg. The patient was continued on same oxygen support for 3 days and then shifted to non-rebreathing mask and finally to face mask oxygenation.

**Case 2:** A 75-year-old male COVID-19 patient having history of myocardial infarction was admitted to the intensive care unit with respiratory distress. Patient was started on remdesivir, dexamethasone, low molecular weight heparin and put on supplemental oxygenation with non-rebreathing mask at 15 L/min. Chest X-ray showed bilateral diffuse infiltrates. Arterial blood gases on 15 L/min of oxygen by non-rebreathing mask showed severe hypoxia (PaO2/FiO2<100), with a pH 7.45, PaO2 73.2 mmHg, PaCO2 41.7 mmHg and SaO2 92%. He was tachypnoeic with a RR > 40/min. We gave additional supplemental oxygen by nasal prong at 6 L/min by another flow meter [Fig. 1]. After that the patient became more comfortable, and peripheral SaO2 increased to 98%. After 30 min of supplemental oxygen, arterial blood gases showed a pH of 7.45, PaO2 100.4 mmHg, PaCO2 39 mmHg, and SaO2 98%. The patient was continued on same oxygen support for 6 days and then shifted to non-rebreathing mask and subsequently to face mask oxygenation.

![Nasal prong and Nonrebreathing mask](image)

**Fig. 1.** Patient on non-rebreathing mask, with low flow nasal oxygen supplementation.

through mouth would increase the oxygen concentration of mask and thus decreases the CO2 concentration and hence rebreathing. We evaluated the effectiveness of the assembly in some of the patients who were not maintaining oxygenation on non-rebreathing mask and found it to be effective in increasing oxygenation. Interestingly, none of our patients had subjective complaints of discomfort by use of this assembly.

The possible mechanisms of oxygenation improvement could be: 1. improved oxygen-air mixing in large airways, 2. increased be: 1. improved oxygen-air mixing in large airways, 2. increased rebreathing of CO2 from the non-rebreathing mask, 3. decrease in rebreathing CO2 from the non-rebreathing mask. This method of oxygen supplementation is easy to assemble, cost-effective and helpful in management of acute hypoxemic COVID-19 patients, whenever there is less availability of HFNC machine for the demand. The approximate cost of our assembly is one dollar. Instant increase in oxygenation might have made the patient feeling more comfortable and prevented intubation and its complications in the described cases. The possible complications (dryness of nasal mucosa, and chances of nasal bleeding) of low flow nasal cannula therapy should be considered which using the assembly. The effectiveness and improved patient outcome needs to be established with a randomized controlled trial.

### 3. Conclusion

We suggest that additional low flow nasal cannula oxygen supplementation to improve oxygenation in acute hypoxemic COVID-19 patients under a non-rebreathing mask as useful in resource limited settings instead of high flow nasal cannula oxygenation. Our observation is based on two patients, hence a well conducted randomized controlled trial might be required to substantiate our findings.

### Source of funding

Nil.

### Consent

Taken from the patient.

### Declaration of competing interest

Nil.

### References

[1] Z. Wu, J.M. McGoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention, J. Am. Med. Assoc. 323 (13) (2020) 1239–1242, https://doi.org/10.1001/jama.2020.2648.

[2] K. Liu, X. Liu, Y. Xu, Z. Xu, Y. Huang, S. Chen, et al., Ventilatory Ratio in hypercapnic mechanically ventilated patients with COVID-19 associated ARDS, Ann. J. Respir. Crit. Care Med. 201 (2020) 10.

[3] W. Alhazzani, M.H. Müller, Y.M. Arabi, M. Loeb, M.N. Gong, E. Fan, et al., Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19), Crit. Care Med. (2020), https://doi.org/10.1007/s00134-020-06022-5.

[4] K. Wang, W. Zhao, J. Li, W. Shu, J. Duan, The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China, Ann. Intensive Care 10 (1) (2020) 37.

[5] M. Nishimura, High-flow nasal cannula oxygen therapy in adults, J Intensive Care 3 (1) (2015) 15.